BLRX - BioLineRx Ltd. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BLRX

BIOLINERX LTD.

NASDAQ

$2.21

▲ UP 0.23% (0.01)

KEY STATISTICS

Market Cap$9.53 M

52w High$7.77

52w Low$2.15

Dividend Yield—

Frequency—

P/E-1.19

Volume18.30K

Shares Out.4.35M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Philip A. Serlin

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 27, 2011

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 23, 2026

DayMonday

Rev. Est.$357.50K

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2025-01-30	Reverse	1:40
2019-07-15	Reverse	1:15

INSTITUTIONAL OWNERSHIP

SHARES OWNED

20.24%

HOLDERS

TOP 8 OF 19 · RANKED BY POSITION SIZE

Cvi Holdings, LLC

815.7K sh

$461.68K

Act Capital Management, LLC

Urban Wealth Management, LLC

9.1K sh

$12K

Next Financial Group, Inc

Bnp Paribas Arbitrage, Snc

1.8K sh

$4.14K

PRICE

$2.21 ▲ UP 0.23% (+$0.01)

OVERLAYS

About BioLineRx Ltd.

https://www.biolinerx.com ↗

BioLineRx Ltd. is an Israeli clinical-stage biopharma focused on oncology, developing drugs like Motixafortide and AGI-134, with ongoing trials for cancer, respiratory, and skin conditions, and collaborations with MSD and MD Anderson.

INDUSTRY

Biotechnology

A PRODUCT BIOLINERX LTD. IS KNOWN FOR

APHEXDA® (motixafortide)

APHEXDA® (motixafortide) is BioLineRx's FDA-approved injection for stem cell mobilization in multiple myeloma, actively commercialized and being explored for other cancers like pancreatic cancer.

COMPETITORS

COMPETITOR

AMGN COMPARE

SNY COMPARE

XFOR COMPARE

BioLineRx in 2025

SENTIMENT: + POSITIVE

OTHER · MAY 2025

BioLineRx Stock Surges Over 50% Following Promising Pancreatic Cancer Trial Data Presented at ASCO 2025

In May 2025, BioLineRx presented positive new data from the pilot phase of the CheMo4METPANC Phase 2b clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study, evaluating motixafortide in combination with a PD-1 inhibitor and chemotherapy for metastatic pancreatic cancer, showed an overall response rate of 64% and a disease control rate of 91%, significantly exceeding historical benchmarks. This promising development for a difficult-to-treat cancer captured significant investor attention and resulted in a substantial one-day surge in the company's stock price.

PARTNERSHIP · SEPTEMBER 2025 · IN PROGRESS

BioLineRx Forms Joint Venture with Hemispherian to Co-Develop a New, First-in-Class Cancer Therapy

BioLineRx established a joint venture with Norwegian biotech Hemispherian to develop GLIX1, a novel, oral small molecule for treating glioblastoma and other cancers. This partnership significantly expands BioLineRx's development pipeline with a first-in-class asset in a high-need oncology area.

Latest News

PRNEWSWIRE · OCT 8, 2026

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philadelphia, Pennsylvania.

READ ARTICLE